Media Release

Basel, 16 October 2014

Roche delivers solid sales growth for the first nine months of 2014

  • Group sales up 5% at CER1, stable in Swiss francs
  • 4% higher sales in Pharmaceuticals Division, with strong growth of oncology portfolio, as well as Actemra for rheumatoid arthritis and Xolair for asthma and chronic hives
  • 6% higher sales in Diagnostics Division, driven by strong Professional Diagnostics’ performance
  • Acquisition of InterMune completed, FDA approval of Esbriet
  • New generation of fully-automated PCR testing systems launched
  • Full year outlook confirmed
Nine months’ sales Jan–Sept
In millions
of CHF
As % of
% change
2014201320142013At CER1In CHF
Group Sales34,75734,86710010050
Pharmaceuticals Division26,96527,19078784-1
- US11,52811,429333351
- Europe7,0706,952202032
- Japan2,4062,492777-3
- International*5,9616,31718183-6
Diagnostics Division7,7927,677222261

* Asia–Pacific, EEMEA (Eastern Europe, Middle East, Africa), Latin America, Canada, Others

Commenting on the nine month results, Roche CEO Severin Schwan said: “Demand for our products is strong in both divisions and we are well on track to reach our full-year targets. We have had positive news from our product pipeline, including study results for Perjeta in breast cancer and a new combination therapy with Zelboraf in melanoma. The InterMune acquisition has also strengthened our portfolio with a new medicine, Esbriet for idiopathic pulmonary fibrosis, which has now been approved by the FDA. In Diagnostics, growth continues to be driven by the immunodiagnostics business and we have strengthened our molecular diagnostics portfolio with a new generation of testing systems.”

Group nine months overview

Group sales were 34.8 billion Swiss francs, 5% higher at constant exchange rates and stable in Swiss francs for the nine months ended 30 September 2014. A number of currencies remained weaker against the Swiss franc throughout the year, most notably the US dollar, as well as all Latin American currencies and the Japanese yen.

Both divisions saw good sales growth for the nine months, with Pharmaceuticals up 4% and Diagnostics up 6%. Growth in the Pharmaceuticals Division was driven by the oncology portfolio, in particular the medicines for HER2-positive breast cancer, Herceptin, Perjeta and Kadcyla, whilst growth in Diagnostics mainly stemmed from a continued strong performance in Professional Diagnostics.

Recent highlights included new approvals for Avastin in cervical cancer in the United States and platinum-resistant ovarian cancer in Europe, and of Gazyvaro in Europe for chronic lymphocytic leukemia. In Diagnostics, the cobas 6800 and cobas 8800 integrated laboratory testing instruments were launched. The Diagnostics division also launched a global access programme for HIV viral load testing in resource constrained countries, in partnership with a number of organisations, including UNAIDS, the Clinton Access Initiative and the President’s Emergency Plan for AIDS relief. Another achievement was Roche being named the Group Leader for the Pharmaceuticals, Biotechnology and Life Sciences Industry in the Dow Jones Sustainability Indices for the sixth year running.

Acquisition of InterMune

The acquisition of InterMune was completed in September, adding a new medicine for idiopathic pulmonary fibrosis, Esbriet which was approved by the FDA in October 2014. Idiopathic pulmonary fibrosis is a progressive disease, which causes scarring of the lungs and has a survival rate of 2 to 3 years from diagnosis. Esbriet has the potential to make a considerable difference to the treatment of patients with this debilitating disease. Roche has successfully issued bonds to the value of 5.75 billion US dollars to finance the transaction.

Pipeline update

At the European Society for Medical Oncology (ESMO) annual congress in September, Roche presented final overall survival data from the Phase III CLEOPATRA study of Perjeta in HER2-positive metastatic breast cancer. The results showed that in combination with Herceptin and chemotherapy, Perjeta extended overall survival by 15.7 months, compared with Herceptin and chemotherapy alone. Results of the Phase III coBRIM study, testing the combination of Zelboraf and the Roche investigational MEK inhibitor, cobimetinib, in patients with malignant melanoma were also presented. The data showed that treatment with the combination halved the risk of the disease worsening. Other highlights at ESMO included encouraging data from early phase trials of an investigational cancer immunotherapy medicine, anti-PDL1 (MPDL3280A) in bladder cancer, a disease for which the drug has received FDA Breakthrough Therapy Designation. There was also positive early data for anti-PDL1 in combination with Avastin in renal cell carcinoma and other solid tumours. Cancer immunotherapy is a new approach that aims to enable the body’s immune system to fight cancer.

Other positive pipeline news came in two Phase III studies (IMELDA and TANIA) for Avastin in treatment for HER2-negative breast cancer, the most common form of breast cancer, showing significant improvements in progression-free survival. Phase III trials for lampalizumab, the first potential treatment for geographic atrophy, were initiated in September. Geographic atrophy is an advanced form of age-related macular degeneration, a progressive condition that can lead to blindness. In Japan, Alecensa (alectinib) was approved for the treatment of ALK-positive non-small cell lung cancer in July, based on the results of a Japanese trial. The FDA has granted Breakthrough Therapy Designation for alectinib and global studies are ongoing.

Full-year outlook confirmed

For the full year 2014, Roche expects low- to mid-single digit growth in Group sales at constant exchange rates. Core EPS is targeted to grow ahead of sales. Roche expects to further increase its dividend.

Read full media release

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

All trademarks used or mentioned in this release are protected by law.

Disclaimer: Cautionary statement regarding forward-looking statements
This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

1) Unless otherwise stated, all growth rates in this document are in constant exchange rates CER (average full-year 2013).